What changed
$VRTX — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $3.0B | EPS $4.47 vs $4.31 🟢 | Margin 38.1%
💡 Consensus values Vertex mostly on its CF franchise, assigning minimal credit to the pain pipeline due to regulatory and commercial uncertainty. Our variant view is that suzetrigine approval is higher probability than implied (base rate for novel non-opioid pain drugs with positive Phase 3 data is ~70-80% approval), and eventual peak sales of $3-5B...
📉 Reward/risk: 3.2:1
🏢 Business Quality: 8/10 - Wide moat in CF with patent protection through 2037, 90%+ gross margins, strong pipeline with multiple shots on goal, and high barriers to entry in rare disease.
📊 Valuation: fair - 25.9x TTM PE is at the 50th percentile of its own limited history, but above large-cap pharma peers (15-20x).
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/VRTX0617